leadf
logo-loader
viewSareum Holdings PLC

Sareum Holdings new licensing deal 'could generate significant near-term milestone revenue'

Sareum Holdings PLC's (LON:SAR) Tim Mitchell speaks to Proactive's Andrew Scott soon after announcing a licensing deal with an unnamed Chinese specialty pharmaceutical company.

The firm will develop Sareum's FLT3+Aurora kinases portfolio, including SAR-20293, a preclinical drug candidate for acute myeloid leukaemia and other blood-borne cancers.

Quick facts: Sareum Holdings PLC

Price: 0.8 GBX

AIM:SAR
Market: AIM
Market Cap: £26.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read